This week, our President and Managing Director, Jennifer Che, attended the Asia Summit for Global Health at the Hong Kong Convention and Exhibition Centre (HKCEC). She was truly impressed by the variety of health-related start-ups, projects, prototypes, and collaborations showcased at the event. The advancements in therapeutics, traditional Chinese medicine, diagnostics, surgical equipment, robotics, and AI solutions highlighted the dynamic biotech landscape of Hong Kong today—a stark contrast to when she first arrived.

Jennifer particularly noted the remarkable initiatives emerging from the InnoHK Centres, which stem from collaborations between local and international universities. Reflecting on the event, she echoed Nancy Ip's sentiment at the HKUST reception: “We can’t do it alone. The most important thing is to collaborate.” This collaborative spirit is vital for driving innovation and improving global health outcomes.

我们的过去活动

Recommended Insights

China’s Newest Examination Guidelines: Post-Filing Supplemental Data for Compounds (Part I)

2021年4月28日
Post-filing data in China has been a constant issue for many patent practitioners around the world. Examiners seem to require it often, and yet the rules regarding when it is acceptable have seemed much stricter than other jurisdictions worldwide. In fact, we tried to summarize the latest state of the law in an earlier blog […]

How a Secondhand Ground Brush Wiped Away a Chinese Patent

2024年12月4日
A Chinese robot vacuum company digs up “hidden evidence” to successfully invalidate a patent owned by its biggest competitor.  Highlights Background  With the growth of online shopping, it is easier than ever to provide evidence of a sale when the product is still being sold on the market. But what if the product is no […]

CHINA: How Prohibiting "Illegal" Inventions Runs into Food Safety Law

2021年10月22日
Chinese Patent Law has an interesting provision that specifically prohibits patent protection on “illegal” or “immoral” inventions. What does this mean, exactly? According to Article 5.1 of the Chinese Patent Law, “no patent shall be granted for an invention that contravenes any law or social moral or that is detrimental to public interests.” On its […]

Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data

2025年4月1日
“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]
Top crossarrow-right